NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

As they prepare for Phase One clinical trials, Corsair Pharma is prioritizing safety, tolerability, and quality at every stage of development. To support these critical goals, the company has ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

Keros Therapeutics (NASDAQ:KROS) faced a downgrade in stock rating from Buy to Neutral by Cantor Fitzgerald. The stock, which ...

The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...